Cipla Limited — Q1FY27 Earnings Call Summary

CIPLA · Q1FY27 · Filed 27 Jul 2026

Key Takeaways

• U.S. pipeline includes 3 respiratory and 1 peptide launch; $1B exit revenue target maintained
• Multiple analyst queries on U.S. launches and margin trajectory; mgmt expects margin improvement with new products
• Q1 FY27 revenue INR 7,119 Cr, +2% y-y (adjusted ~4% growth)
• North America revenue $162M; Ventolin generic launched, ramp expected by FY end
• Gross margin 62.5%, impacted by product mix, war costs, inventory charges
• EBITDA margin 16.7% excluding other income; PAT INR 789 Cr (11% of sales)
• One India business grew 12% y-y; branded prescription up 15.4%
• R&D spend INR 486 Cr (6.8% of revenue); net cash INR 9,494 Cr post dividend
• South Africa private market grew 6.5%, tender business declined
• New CFO Dinesh Jain appointed; outgoing CFO Ashish Adukia thanked

📄 Source: View original transcript (PDF)

Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.